BEIJING: A Covid-19 vaccine developed by a state-owned Chinese pharmaceutical company was administered to about one million people under the government’s emergency use scheme, the company’s president said.
“In terms of emergency use, the vaccines were given to almost a million people and there has not been a single case of a serious adverse event. People have only had mild symptoms, ”said Liu Jingzhen, president of the China National Pharmaceutical Group (Sinopharm).
“So far, all of our progress, from research to clinical trials, production and emergency use, we have been leading the world,” Hong Kong-based South China Morning Post said on Thursday, citing Liu to a Chinese digital media publication.
His comments came amid criticism that Chinese companies have not released clinical data from their vaccine studies.
In addition to the recipients of the Sinopharm blows, the Zhejiang authorities said they had made available to high-risk groups in the eastern province of China a Covid-19 vaccine developed by the private pharmaceutical company Sinovac Biotec under the use scheme. of emergency.
Meanwhile, the Lancet Infectious Diseases said that a vaccine candidate for the inactivated Covid-19 vaccine in China has been shown to be safe and tolerable and can induce a rapid immune response.
The level of antibodies induced by the vaccine was lower than that of people who had recovered from Covid-19, while it was able to protect the human body from infections caused by the virus, the state-run Xinhua reported. citing the Lancet findings.
The vaccine, CoronaVac, was developed by Chinese biopharmaceutical producer Sinovac Biotech.
It was tested in randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trials involving more than 700 healthy adults ages 18 to 59.
Vaccination is done with two doses taken 14 days apart and the candidate vaccine is effective, making it suitable for emergency use amid the pandemic, said Zhu Fengcai, one of the authors of the findings.
Zhu added that more research is needed to verify the duration of the immune response induced by vaccination.
The candidate vaccine is currently undergoing phase 3 clinical trials to confirm its efficacy.
“In terms of emergency use, the vaccines were given to almost a million people and there has not been a single case of a serious adverse event. People have only had mild symptoms, ”said Liu Jingzhen, president of the China National Pharmaceutical Group (Sinopharm).
“So far, all of our progress, from research to clinical trials, production and emergency use, we have been leading the world,” Hong Kong-based South China Morning Post said on Thursday, citing Liu to a Chinese digital media publication.
His comments came amid criticism that Chinese companies have not released clinical data from their vaccine studies.
In addition to the recipients of the Sinopharm blows, the Zhejiang authorities said they had made available to high-risk groups in the eastern province of China a Covid-19 vaccine developed by the private pharmaceutical company Sinovac Biotec under the use scheme. of emergency.
Meanwhile, the Lancet Infectious Diseases said that a vaccine candidate for the inactivated Covid-19 vaccine in China has been shown to be safe and tolerable and can induce a rapid immune response.
The level of antibodies induced by the vaccine was lower than that of people who had recovered from Covid-19, while it was able to protect the human body from infections caused by the virus, the state-run Xinhua reported. citing the Lancet findings.
The vaccine, CoronaVac, was developed by Chinese biopharmaceutical producer Sinovac Biotech.
It was tested in randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trials involving more than 700 healthy adults ages 18 to 59.
Vaccination is done with two doses taken 14 days apart and the candidate vaccine is effective, making it suitable for emergency use amid the pandemic, said Zhu Fengcai, one of the authors of the findings.
Zhu added that more research is needed to verify the duration of the immune response induced by vaccination.
The candidate vaccine is currently undergoing phase 3 clinical trials to confirm its efficacy.
.
